1. PI-001
    5HT RECEPTOR OCCUPANCY (RO) IN HEALTHY SUBJECTS DETERMINED BY POSITRON EMISSION TOMOGRAPHY (PET) FOLLOWING SINGLE-DOSE ADMINISTRATION OF SAM760 (PF‑05212377).
  2. PI-002
    VARIABILITY OF TRIMETHOPRIM BIOACTIVATION IN CHILDREN.
  3. PI-003
    EFFECTS OF VARENICLINE IN HUMAN LABORATORY MODELS FOR SCREENING OF PHARMACOTHERAPEUTICS FOR ALCOHOL USE DISORDER.
  4. PI-004
    OXYLIPID PROFILE OF LOW-DOSE ASPIRIN EXPOSURE- A PHARMACOMETABOLOMICS STUDY.
  5. PI-005
    MATERNAL HAIR AS A BIOMARKER TO ASSESS POLYBROMINATED DIPHENYL ETHER (PBDE) EXPOSURE IN MALE INFANTS WITH HYPOSPADIAS.
  6. PI-006
    COST-EFFECTIVENESS OF GENOTYPE-GUIDED WARFARIN DOSING IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT UNDER FEE-FOR-SERVICE SYSTEM.
  7. PI-007
    EVALUATION OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF MULTIPLE ORAL DOSES OF CC-220 IN HEALTHY SUBJECTS.
  8. PI-008
    WHAT IS THE IMPACT OF "PROFESSIONAL SUBJECTS" ON MEDICATION EFFICACY TRIALS?
  9. PI-009
    INVERTED U-SHAPED (UMBRELLA OR BELL-SHAPED) DOSE RESPONSE RELATIONSHIP: DOES IT OCCUR AND WHAT ARE THE LIKELY LEAD CANDIDATES TO CONSIDER IN DRUG DEVELOPMENT?
  10. PI-010
    SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF LC23-1306 IN SINGLE OR MULTIPLE ADMINISTRATIONS.
  11. PI-011
    DRUG-DRUG INTERACTIONS OF CARBAMAZEPINE WITH THE HCV DIRECT ACTING ANTIVIRAL (DAA) COMBINATION OF ABT-450/R, OMBITASVIR AND DASABUVIR.
  12. PI-012
    DRUG-DRUG INTERACTIONS OF PRAVASTATIN AND ROSUVASTATIN WITH THE DIRECT ACTING ANTIVIRAL COMBINATION OF ABT-450/R, OMBITASVIR ± DASABUVIR IN HEALTHY VOLUNTEERS.
  13. PI-013
    PHARMACOKINETIC INTERACTION OF HCV NS3/4A PROTEASE INHIBITOR VANIPREVIR AND ROSUVASTATIN.
  14. PI-014
    PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE COADMINISTRATION OF KETOCONAZOLE WITH ABT-450/R, OMBITASVIR AND DASABUVIR IN HEALTHY ADULT SUBJECTS.
  15. PI-015
    DRUG-DRUG INTERACTIONS OF DIGOXIN WITH THE HCV DIRECT ACTING ANTIVIRAL (DAA) COMBINATION OF ABT-450/R, OMBITASVIR AND DASABUVIR.
  16. PI-016
    EXPOSURE-SAFETY RESPONSE RELATIONSHIP FOR ABT-450/RITONAVIR, OMBITASVIR, DASABUVIR AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 VIRUS-INFECTED SUBJECTS IN PHASE III STUDIES.
  17. PI-017
    EXPLORING <i>IN VITRO</i> ANTIPSEUDOMONAL ACTIVITY OF SYNERGISTIC TIGECYCLINE-TETRACYCLINE COMBINATIONS.
  18. PI-018
    GENETIC ASSOCIATIONS WITH WARFARIN RESPONSE IN PATIENTS RECEIVING GENOTYPE-GUIDED DOSING.
  19. PI-019
    OATP1B1 T521C POLYMORPHISM (RS4149056) DOES NOT AFFECT THE PHARMACOKINETICS OF EDOXABAN.
  20. PI-020
    INFLUENCE OF CARBOXYLESTERASE 1 <i>(CES1)</i> GENETIC POLYMORPHISM ON PHARMACOKINETIC CHARACTERISTICS OF OSELTAMIVIR IN HEALTHY KOREAN SUBJECTS.
  21. PI-021
    EFFECTS OF UGT1A1 GENETIC VARIANTS ON PHARMACOKINETICS AND TOXICITIES OF BELINOSTAT ADMINSTERED BY CONTINUOUS INFUSION IN COMBINATION WITH CISPLATIN AND ETOPOSIDE.
  22. PI-022
    GENOME-WIDE ASSOCIATION STUDY OF PLATELET FACTOR 4/HEPARIN ANTIBODY FORMATION.
  23. PI-023
    MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 4 MAY CONTRIBUTE TO BETA-LACTAM INDUCED NEUTROPENIA.
  24. PI-024
    EVALUATION OF THE IMPACT OF UGT1A1 PROMOTER VARIANTS ON BILIRUBIN LEVELS IN HYPERBILIRUBINEMIC PATIENTS.
  25. PI-025
    EFFECTS OF TRICYCLIC COMPOUNDS ON NARATRIPTAN TRANSPORT THROUGH OATP1A2.
  26. PI-026
    CHARACTERIZATION OF P450 ENZYME INVOLVEMENT IN THE FORMATION OF TRIMETHOPRIM PRIMARY METABOLITES.
  27. PI-027
    PHARMACOMETABOLOMICS STUDY: REVEALS THAT METFORMIN TREATMENT IMPACTS THE UREA CYCLE.
  28. PI-028
    A PHARMACOGENOMIC STUDY ON THE PHARMACOKINETICS OF TACROLIMUS IN HEALTHY VOLUNTEERS USING THE AFFYMETRIX DMET PLUS PLATFORM.
  29. PI-029
    ANTI-HIV PROTEASE INHIBITORS MAY AGGRAVATE RIFAMPICIN INDUCED LIVER INJURY THROUGH MULTIFACETED INTERACTIONS ON HEPATIC TRANSPORTERS.
  30. PI-030
    A PHARMACOMETRICS APPROACH COMBINED WITH VARIOUS GENETIC ANALYSES UNCOVERS GENES LINKED TO THE DYNAMICS OF HBA1C.
  31. PI-031
    COMPARISON OF DRUG-TRANSPORTER MRNA EXPRESSION LEVELS IN PBMC FROM HIV-INFECTED PATIENTS WITH AND WITHOUT DIABETES.
  32. PI-032
    METABOLOMICS, GENOMICS AND LIPIDOMICS REVEAL NOVEL SIGNATURES OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
  33. PI-033
    ORANGE JUICE AND APPLE JUICE INGREDIENTS INHIBIT DASATINIB EFFLUX VIA P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN: A NEW TYPE OF BEVERAGE-DRUG INTERACTION.
  34. PI-034
    IDENTIFICATION OF CONSERVED HYPOXIA-INDUCED GENOMIC PATHWAYS THAT DRIVE AGGRESSIVE NEUROBLASTOMA PHENOTYPES.
  35. PI-035
    OPTIMIZATION OF THE DOSE OF IRINOTECAN IN CANCER PATIENTS WITH SEVERE RENAL FAILURE (SRF) BASED ON PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL.
  36. PI-036
    GRAPEFRUIT JUICE INGREDIENTS INTERACT WITH DASATINIB THROUGH INHIBITION OF BREAST CANCER RESISTANCE PROTEIN: A NEW TYPE OF BEVERAGE-DRUG INTERACTION.
  37. PI-037
    EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF AXITINIB.
  38. PI-038
    <i>IN VITRO</i> MOLECULAR IMAGING OF UNLABELED DRUGS IN HUMAN TUMOR SPECIMENS USING IMAGING MASS SPECTROMETRY.
  39. PI-039
    ANALYZING THE CLINICAL ACTIONABILITY OF GERMLINE PHARMACOGENOMIC (PGX) DATA IN ONCOLOGY (ONC).
  40. PI-040
    PHARMACOKINETICS OF ANTIBODY-DRUG CONJUGATE (ADC) - DNIB0600A IN A PHASE I STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (OC) / NON-SMALL CELL LUNG CANCER (NSCLC).
  41. PI-041
    EVALUATION OF THE EFFECT OF MOMELOTINIB ON THE QT/QTC INTERVAL IN HEALTHY SUBJECTS.
  42. PI-042
    DRUG INTERACTION PROFILE OF MOMELOTINIB.
  43. PI-043
    EFFECT OF HIGH SODIUM INTAKE ON PHARMACOKINETICS OF FIMASARTAN, AN ANGIOTENSIN RECEPTOR TYPE I BLOCKER, IN HEALTHY SUBJECTS.
  44. PI-044
    MODEL-BASED META-ANALYSIS (MBMA) OF THE HbA1c LOWERING EFFECT OF SGLT-2 INHIBITORS (SGLT2i): IMPACT OF BASELINE HbA1c, RENAL FUNCTION AND BACKGROUND TREATMENT.
  45. PI-045
    STRATEGY TO EVALUATE AMG 853 1-<i>β-O</i>-ACYL GLUCURONIDE EARLY IN CLINICAL DEVELOPMENT.
  46. PI-046
    COLLECTION OF FLUIDS FROM THE UPPER SMALL INTESTINE OF HEALTHY SUBJECTS IN FASTED AND FED CONDITION FOR THE <i>EX VIVO</i> ASSESSMENT OF SOLUBILITY AND DISSOLUTION OF DRUG PRODUCTS.
  47. PI-047
    USING INNOVATIVE COMPUTATIONAL TOOLS TO IDENTIFY THE CLINICALLY IMPORTANT DRIVERS OF VARIABILITY IN CLOPIDOGREL ANTIPLATELET THERAPY.
  48. PI-048
    PHARMACOKINETICS OF AN ANTIBODY-DRUG CONJUGATE (ADC) - DMUC5754A IN A PHASE I STUDY WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) OR UNRESECTABLE PANCREATIC CANCER (PANC).
  49. PI-049
    SYSTEMATIC ASSESSMENT OF INTESTINAL METABOLISM AND DEGREE OF INHIBITION IN DRUG-DRUG INTERACTIONS CAUSED BY INHIBITION OF CYP3A.
  50. PI-050
    OBSERVED LONG PLASMA TERMINAL HALF-LIFE OF ANACETRAPIB IS ASSOCIATED WITH ADIPOSE DEPOSITION: PLASMA AND ADIPOSE PHARMACOKINETICS IN MICE AND HUMANS.
  51. PI-051
    DEVELOPMENT OF A HUMAN WHOLE-BODY PHYSIOLOGICALLY-BASED PHARMACOKINETIC (WB-PBPK) MODEL OF LOVASTATIN LACTONE AND CARBOXYLATE (ACID) TO PREDICT HEPATIC CONCENTRATIONS.
  52. PI-052
    TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PI-BASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).
  53. PI-053
    THE ROLE OF MRP3 IN THE GENERATION OF CLOPIDOGREL ACTIVE METABOLITE.
  54. PI-054
    EFFECT OF GRAPEFRUIT JUICE ON THE BIOACTIVATION OF PRASUGREL.
  55. PI-055
    ABSOLUTE ORAL BIOAVAILABILITY OF FIMASARTAN IN HEALTHY KOREAN ADULT MALE VOLUNTEERS.
  56. PI-056
    PBPK MODELLING AND SIMULATION IN CHILDREN FOR TAPENTADOL METABOLIZED THROUGH GLUCURONIDATION.
  57. PI-057
    UNDERSTANDING OF GFR (GLOMERULAR FILTRATION RATE) CHANGES IN RESPONSE TO ARB ADMINISTRATION USING QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH.
  58. PI-058
    LONGITUDINAL ANALYSIS OF HAM-A FOR EFFICACY IN MONOTHERAPY AND ADJUNCTIVE GAD STUDIES.
  59. PI-059
    PARAMETER ESTIMATION PERFORMANCE FOR SIGMOID E<sub>MAX </sub>MODELS IN EXPOSURE-RESPONSE RELATIONSHIP.
  60. PI-060
    SYSTEMS PHARMACOLOGY MODELING OF ACUTE LYMPHOBLASTIC LEUKEMIA PROGRESSION AND TREATMENT.
  61. PI-061
    MODELING AND SIMULATION TO EVALUATE AZTREONAM DOSE RECOMMENDATION FOR PATIENTS WITH RENAL IMPAIRMENT.
  62. PI-062
    THE SYSTEMS PHARMACOLOGY MODEL OF HEPATITIS C PROGRESSION AND TREATMENT.
  63. PI-063
    QUANTITATIVE STRUCTURE-PHARMACOKINETIC (PK) PROPERTIES-RELATIONSHIPS (QSPKR) FOR TRIPTANS (TRP) IN HUMANS.
  64. PI-064
    A FIRST IN HUMAN TOPICAL STUDY TO CHARACTERIZE THE PHARMACOKINETICS (PK) FOLLOWING ADMINISTRATION OF [<sup>14</sup>C]UMECLIDINIUM (UMEC) TO THE AXILLA OR PALM OF HEALTHY MALE SUBJECTS.
  65. PI-065
    PROBIOTICS FOR INFANTILE COLIC: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL INVESTIGATING LACTOBACILLUS REUTERI DSM 17938.
  66. PI-066
    QUANTITATIVE STRUCTURE-PHARMACOKINETIC (PK) PROPERTIES-RELATIONSHIPS (QSPKR) FOR CLASS III ANTI-ARRHYTHMIC AGENTS (AAR) IN HUMANS.
  67. PI-067
    PHARMACOKINETIC INTERACTION BETWEEN ATORVASTATIN AND METFORMIN AT STEADY-STATE IN HEALTHY KOREAN VOLUNTEERS.
  68. PI-068
    DRUG-SYSTEMS-DISEASE MODEL TO PREDICT TREATMENT-OUTCOME IN TYPE 2 DIABETES MELLITUS.
  69. PI-069
    EFFECTS OF A HIGH-FAT MEAL ON THE RELATIVE ORAL BIOAVAILABILITY OF A FIXED-DOSE COMBINATION OF ATORVASTATIN AND METFORMIN IN HEALTHY KOREAN VOLUNTEERS.
  70. PI-070
    MODELING, SIMULATIONS AND EXTERNAL VALIDATION OF AN OPTIMAL DOSING STRATEGY OF TESTOSTERONE UNDECANOATE IN HYPOGONADAL MEN.
  71. PI-071
    MODEL-BASED ANALYSIS OF NIVOLUMAB TO SUPPORT CLINICAL PHARMACOLOGY PROFILING IN SUBJECTS WITH SOLID TUMORS.
  72. PI-072
    RELATIVE BIOAVAILABILITY OF CRUSHED APIXABAN TABLETS ADMINISTERED WITH WATER OR APPLESAUCE IN HEALTHY SUBJECTS.
  73. PI-073
    CHARACTERIZATION OF EXPOSURE-RESPONSE (E-R) RELATIONSHIP FOR NIVOLUMAB IN SUBJECTS WITH ADVANCED MELANOMA PROGRESSING POST ANTI-CTLA4.
  74. PI-074
    CLOPIDOGREL DOES NOT SIGNIFICANTLY AFFECT THE PHARMACOKINETICS OF SIMVASTATIN: A CROSSOVER STUDY IN HEALTHY VOLUNTEERS .
  75. PI-075
    PHARMACOKINETICS/PHARMACODYNAMICS/PHARMACOGENETICS OF DINACICLIB AND DINACICLIB GLUCURONIDE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.
  76. PI-076
    USE OF PARTIAL AUC TO DEMONSTRATE BIOEQUIVALENCE OF GENERIC METHYLPHENIDATE EXTENDED-RELEASE PRODUCTS USING PHYSIOLOGICALLY BASED ABSORPTION MODELING AND SIMULATION.
  77. PI-077
    <i>IN VITRO</i> METABOLISM OF MONTELUKAST BY CYTOCHROME P450S (CYPS) AND UDP-GLUCURONOSYLTRANSFERASES (UGTS): IMPLICATIONS FOR CYP2C8 PHENOTYPING.
  78. PI-078
    A SNAPSHOT OF PRESCRIBING PRACTICE FOR THE CO-PRESCRIPTION OF CLOPIDOGREL AND ESOMEPRAZOLE IN A UNIVERSITY HOSPITAL.
  79. PI-079
    PROBABILITY OF PK/PD TARGET ATTAINMENT (PTA) FOR ASIAN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED WITH CEFTAROLINE FOSAMIL (CPT-F).
  80. PI-080
    PK/PD ANALYSES AND CLINICAL DOSE SELECTION FOR ZILEUTON IN SICKLE CELL DISEASE PATIENTS.
  81. PI-081
    IMPACT OF ALTERED IN VITRO DISSOLUTION PROFILE ON WARFARIN IN VIVO PHARMACOKINETICS PERFORMANCE- POPULATION PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) SIMULATION.
  82. PI-082
    ALTERED HEPATIC PROTEIN EXPRESSION OF CYP2C AND CYP4A IN MOUSE MODELS OF TYPE I AND TYPE II DIABETES.
  83. PI-083
    MODELING AND SIMULATION TO EVALUATE POSSIBLE CONSEQUENCES OF DOSE DUMPING FOR RBP-7000, A NEW SUSTAINED‐RELEASE FORMULATION OF RISPERIDONE (RIS).
  84. PI-084
    PHYSIOLOGICALLY-BASED ABSORPTION MODELING AND SIMULATION FOR ASSESSING BIOAVAILABILITY IN ELDERLY, CHILDREN AND GASTROINTESTINAL DISEASES.
  85. PI-085
    A GASTRIC PH MODIFIER PANTOPRAZOLE DID NOT SIGNIFICANTLY AFFECT THE ON PHARMACOKINETICS OF FEDRATINIB IN HEALTHY MALE SUBJECTS.
  86. PI-086
    EXPLORATORY EXPOSURE-SAFETY ANALYSES OF INX-08032 IN SUBJECTS WITH HEPATITIS C VIRUS INFECTION RECEIVING BMS-986094 (INX-08189).
  87. PI-087
    OPTIMIZING THE OPERATING CHARACTERISTICS OF DOSE RESPONSE TRIALS BY COMBINING TRADITIONAL AND MODEL-BASED ANALYTICAL APPROACHES.
  88. PI-088
    PHARMACOKINETICS (PK) OF ANTI-MSLN ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH UNRESECTABLE PANCREATIC OR PLATINUM-RESISTANT OVARIAN CANCER IN A PHASE I STUDY.
  89. PI-089
    A POPULATION PHARMACOKINETIC MODEL FOR OPTIMIZED BELINOSTAT DOSING BY CONTINUOUS INFUSION BASED ON UGT1A1 GENOTYPE.
  90. PI-090
    FED AND FASTED COMPARATIVE BIOAVAILABILITY STUDY OF RHB-102 (ONCE-DAILY ONDANSETRON 24 mg EXTENDED-RELEASE TABLETS) IN HEALTHY VOLUNTEERS.
  91. PI-091
    ANALYSIS OF THE IMPACT OF DIFFERENCES IN DOSING ADHERENCE ON THE EXPOSURE PROFILES OF APIXABAN AND RIVAROXABAN .
  92. PI-092
    COMPARATIVE BIOAVAILABILITY STUDY OF RHB-102 (ONDANSETRON 24 mg ER TABLETS QD) VS. ONDANSETRON 8 mg TABLETS BID AND A SINGLE DOSE OF ONDANSETRON 24 mg IN HEALTHY VOLUNTEERS.
  93. PI-093
    PHARMACOKINETIC AND SAFETY EVALUATION OF GS-6637, A PRODRUG OF THE ALDEHYDE DEHYDROGENASE 2 (ALDH2) INHIBITOR GS-548351, IN HEALTHY NON-SMOKERS AND SMOKERS.
  94. PI-094
    POPULATION PHARMACOKINETICS OF THE PARP INHIBITOR VELIPARIB IN WOMEN WITH OVARIAN CANCER.
  95. PI-095
    PROTON PUMP INHIBITORS DO NOT IMPAIR THE EFFECTIVENESS OF METFORMIN IN DIABETIC PATIENTS.
  96. PI-096
    POPULATION PHARMACOKINETICS OF INTRADERMAL VS. SUBCUTANEOUS INSULIN DELIVERY IN PATIENTS WITH TYPE 1 DIABETES.
  97. PI-097
    PANOBINOSTAT PK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
  98. PI-098
    RE-EVALUATION OF NEVIRAPINE METABOLISM BY HUMAN CYTOCHROME P450S (CYPS) <i>IN VITRO</i>.
  99. PI-099
    GENETIC AND DRUG RESPONSE: STUDY ON THE INFLUENCES OF GENETICS IN VARIATION TO MORPHINE RESPONSE.
  100. PI-100
    A TQT STUDY CONFIRMS EARLY PK/PD MODELING THAT A SUPRATHERAPEUTIC DOSE OF OMARIGLIPTIN, A ONCE-WEEKLY DPP 4 INHIBITOR, DOES NOT PROLONG THE QTc INTERVAL.
  101. PI-101
    POLYPHARMACY IN CANCER PATIENTS RECEIVING RADIATION THERAPY.
  102. PI-102
    NATURAL HISTORY OF PULMONARY FUNCTION IN PATIENTS RECEIVING AMIODARONE THERAPY FOR MORE THAN TWO YEARS.
  103. PI-103
    AMBULATORY MONITORING DEMONSTRATES STATISTICALLY DIFFERENT 24-HOUR AND NOCTURNAL BP IN PATIENTS SWITCHING BETWEEN DIFFERING NIFEDIPINE OSMOTIC DELIVERY FORMULATIONS.
  104. PI-104
    NOMOGRAM GUIDED MAINTENANCE DOSE SELECTION AS A TOOL FOR TEACHING BETTER UNDERSTANDING OF THE PHARMACOKINETICS OF AMIODARONE MANAGEMENT.
  105. PI-105
    SIMULATING CARDIAC CONSEQUENCES OF THE GENETIC VARIABILITY AT THE METABOLISM LEVEL WITH USE OF MIDDLE-OUT APPROACH AND FLECAINIDE AS AN EXAMPLE COMPOUND.
  106. PI-106
    COMPARATIVE EFFECTIVENESS AND SAFETY OF CLOZAPINE VERSUS STANDARD ANTIPSYCHOTIC TREATMENT IN ADULTS WITH SCHIZOPHRENIA.
  107. PI-107
    HIGH SYSTEMIC EXPOSURE OF METFORMIN WITH COMPARABLE GLUCOSE LOWERING EFFECT IN HEALTHY ELDERLY SUBJECTS COMPARED TO HEALTHY YOUNGER SUBJECTS.
  108. PI-108
    MAYBE WE JUST NEED TO ASK: KNOWLEDGE AND BELIEFS ABOUT CLINICAL AND GENETIC RESEARCH AMONG AFRICAN AMERICAN COMMUNITY MEMBERS.
  109. PI-109
    PLACENTAL TRANSFER OF INSULIN DETEMIR <i>IN VIVO</i>.
  110. PI-110
    PREVALENCE OF HEAVY FETAL ALCOHOL EXPOSURE IN CANADA: A POPULATION BASED MECONIUM STUDY.
  111. PI-111
    CHARACTERIZING THE CHANGES IN DRUG CLEARANCE FROM NEONATES TO ADULTS BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING USING GASTROPLUS.
  112. PI-112
    MDR1, MRP2, OATP2B1 AND PEPT1 TRANSPORTER PROTEIN IS PRESENT IN HUMAN NEONATAL AND INFANT SMALL INTESTINE.
  113. PI-113
    EXTENDED INTERVAL GENTAMICIN DOSING IN PRETERM INFANTS LESS THAN 35 WEEKS CORRECTED GESTATIONAL AGE.
  114. PI-114
    THE EFFECTS OF BODY WEIGHT/BODY MASS INDEX ON THE DISPOSITION OF LEVONORGESTREL AFTER A SINGLE DOSE ADMINISTRATION OF LEVONORGESTREL CONTAINING EMERGENCY CONTRACTIVES.
  115. PI-115
    PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF DA-3091 AFTER SUBCUTANEOUS INJECTION IN HEALTHY SUBJECTS.
  116. PI-116
    TIME TO EVENT MODELING OF CODRITUZUMAB(GC33) ON OVERALL SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.
  117. PI-117
    AN OPEN-LABEL STUDY IN HEALTHY MEN TO EVALUATE THE CONCENTRATION OF DENOSUMAB IN SEMINAL FLUID.
  118. PI-118
    DACLIZUMAB HIGH YIELD PROCESS HAS NO EFFECT ON ACTIVITY OF THE CYTOCHROME P450 ENZYMES: RESULTS OF A DRUG COCKTAIL INTERACTION STUDY IN SUBJECTS WITH MULTIPLE SCLEROSIS.
  119. PI-119
    MODEL-BASED MINIMUM ANTICIPATED BIOLOGICAL EFFECT LEVEL (MABEL) APPROACH LED TO SAFE HUMAN STARTING DOSE OF THREE DOMAIN ANTIBODIES FOR AUTOIMMUNE DISEASES.
  120. PI-120
    MODEL-BASED META-ANALYSIS OF THE CLINICAL EFFICACY OF ANTI-PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9) MONOCLONAL ANTIBODIES.
  121. PII-001
    THE COMPLEXITY AND DYNAMICS OF TUMOR RESPONSE TO VORINOSTAT CAN BE ELUCIDATED BY INTEGRATING MULTIPLE LARGE HIGH-THROUGHPUT DATASETS.
  122. PII-002
    <i>IN VITRO</i>-<i>IN VIVO</i> CORRELATION (IVIVC) OF DRUG INDUCED INHIBITION OF CREATININE TUBULAR SECRETION USING MDCK CELLS EXPRESSING OCT2/OAT2/OCT3/MATE1/MATE2K TRANSPORTERS.
  123. PII-003
    ENDOGENOUS BILE ACIDS ARE POTENTIAL BIOMARKERS FOR OATP1B3 ACTIVITY.
  124. PII-004
    GENOME WIDE ASSOCIATION ANALYSIS WITH AMINE METABOLITES REVEALS NOVEL LOCI IMPACTING HUMAN METABOLOMIC PROFILES.
  125. PII-005
    EFFECTS OF CC-220, AN ORAL IMMUNOMODULATOR, ON IMMUNE RESPONSES.
  126. PII-006
    INTERACTIVE GENOTYPE-BASED DOSING GUIDELINES.
  127. PII-007
    PRECLINICAL EFFICACY OF T-LAK CELL-ORIGINATED PROTEIN KINASE INHIBITOR IN FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA.
  128. PII-008
    PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL PREDICTIONS OF CYP MEDIATED DDIS: POTENTIAL INTERACTIONS BETWEEN ICA-105665 AND CYP ENZYME INDUCERS.
  129. PII-009
    INTRA-ARTERIAL MICRODOSING (IAM), A NOVEL DRUG DEVELOPMENT APPROACH, PROOF OF CONCEPT IN RATS.
  130. PII-010
    PHARMACOKINETIC INTERACTION BETWEEN ROSUVASTATIN AND FENOFIBRATE IN HEALTHY VOLUNTEERS.
  131. PII-011
    EXPLORATORY HUMAN ABUSE POTENTIAL ASSESSMENT OF CENTANAFADINE, A NOVEL TRIPLE REUPTAKE INHIBITOR.
  132. PII-012
    STATIN INHIBITION OF LACTIC ACID TRANSPORT IN HUMAN SKELETAL MUSCLE.
  133. PII-013
    IDENTIFICATION AND FUNCTIONAL STUDIES OF CYP4V2 VARIANTS AMONG KOREAN POPULATION.
  134. PII-014
    THE EFFECT OF INTRACELLULAR METHADONE ON HERG CURRENT IS MODULATED BY THE COEXPRESSION OF THE CYP450 ISOZYME 2B6.
  135. PII-015
    ILOPERIDONE METABOLISM IN HUMAN HEART.
  136. PII-016
    THE EFFECT OF CIGARETTE SMOKING ON THE PLASMA AND URINE EICOSANOID METABOLIC PROFILE IN A HEALTHY MALE POPULATION.
  137. PII-017
    CYP2D6 GENE COPY NUMBER VARIATION (CNV): HOW ACCURATE IS THE AFFYMETRIX CytoScan HD?.
  138. PII-018
    METABOLISM OF OLANZAPINE IN HUMAN HEART MICROSOMES.
  139. PII-019
    PHARMACOGENOMICS OF MITHRAMYCIN-INDUCED HEPTATOTOXICITY.
  140. PII-020
    RHEIN ELICITS <i>IN VITRO</i> CYTOTOXICITY IN PRIMARY HUMAN LIVER L-02 (HL-7702) CELLS BY INDUCING APOPTOSIS VIA MITOCHONDRIA-MEDIATED PATHWAY.
  141. PII-021
    RIFAMPIN REGULATION OF DRUG TRANSPORTERS AND THE ROLE OF MICRORNA IN HUMAN HEPATOCYTES.
  142. PII-022
    ABC TRANSPORTER POLYMORPHISMS ARE ASSOCIATED WITH IRINOTECAN EXPOSURE AND NEUTROPENIA.
  143. PII-023
    INTERINDIVIDUAL VARIABILITY IN CYP2D6 ACTIVITY IN HUMAN LIVER MICROSOMES TO CHARACTERIZE RARE GENETIC VARIATION.
  144. PII-024
    P-MAP: NETWORK BIOLOGY APPLIED TO DETERMINE CELLULAR SENSITIVITY OF DRUG RESPONSE IN TRIPLE NEGATIVE BREAST CANCER CELL LINES.
  145. PII-025
    INTENSIVE STATINS EXHIBIT VARIABLE PARADOXICAL EFFECTS WHEN COMBINED WITH FIBRATES IN A MODEL OF CARDIOVASCULAR DISEASE.
  146. PII-026
    GENOME-WIDE ASSOCIATION STUDY TO IDENTIFY SUSCEPTIBILITY LOCI ASSOCIATED WITH HEMORRHAGIC COMPLICATIONS AMONG AFRICAN AMERICAN PATIENTS ON STABLE WARFARIN DOSE.
  147. PII-027
    ASSESSMENT OF THE POTENTIAL FOR DRUG-DRUG INTERACTIONS BETWEEN TRASTUZUMAB EMTANSINE (T-DM1) AND CYP3A INHIBITORS OR INDUCERS AND THE IMPACT ON ITS PK AND SAFETY.
  148. PII-028
    POPULATION PHARMACOKINETIC (PPK) MODELING OF AXITINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED THYROID CANCER.
  149. PII-029
    POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF VORINOSTAT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH VARYING DEGREES OF HEPATIC FUNCTION.
  150. PII-030
    TARGETING TUMOR-ASSOCIATED HYPOXIA TO OVERCOME CHEMORESISTANCE IN PANCREATIC DUCTAL ADENOCARCINOMA (PDA).
  151. PII-031
    A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.
  152. PII-032
    A MODEL RELATING OVERALL SURVIVAL RELATED TO TUMOR GROWTH INHIBITION IN RENAL CELL CARCINOMA PATIENTS TREATED WITH SUNITINIB, AXITINIB OR TEMSIROLIMUS.
  153. PII-033
    POPULATION PHARMACOKINETICS OF BEVACIZUMAB: ANALYSIS OF INDIVIDUAL DATA FROM 1,792 PATIENTS WITH SOLID TUMORS FROM 15 STUDIES.
  154. PII-034
    EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.
  155. PII-035
    DIFFERENCES IN MYCOPHENOLIC ACID AND METABOLITE, MYCOPHENOLIC ACID GLUCURONIDE EXPOSURES BETWEEN CALCINEURIN INHIBITOR REGIMENS POST-RENAL TRANSPLANT.
  156. PII-036
    ALTERED VITAMIN A HOMEOSTASIS IN CHRONIC KIDNEY DISEASE.
  157. PII-037
    SEARCHING FOR OPTIMAL THERAPY OF THE AMYLOID PATHOLOGY USING MECHANISM-BASED MODEL.
  158. PII-038
    GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NOVEL SUSCEPTIBILITY LOCI FOR VENOUS THROMBOEMBOLISM IN AFRICAN AMERICANS.
  159. PII-039
    A TWO-WEEK COURSE OF HIGH-DOSE INTEGRASE INHIBITORS DOES NOT LEAD TO NEPHROTOXICITY IN MICE.
  160. PII-040
    NOVEL METHODOLOGY FOR ESTIMATING THE TREATMENT EFFECT IN PRESENCE OF HIGHLY VARIABLE PLACEBO RESPONSE.
  161. PII-041
    INVESTIGATION INTO THE INTERCHANGEABILITY OF GENERIC FORMULATIONS USING A RANDOM SELECTION OF MEDICINES AND IMMUNOSUPPRESSANTS.
  162. PII-042
    A PHASE I STUDY TO DETERMINE THE SINGLE DOSE SAFETY AND PHARMACOKINETICS OF SYM-1219 (SECNIDAZOLE) IN HEALTHY FEMALE VOLUNTEERS.
  163. PII-043
    EFFECT OF FOOD ON THE PHARMACOKINETICS OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB IN HEALTHY SUBJECTS.
  164. PII-044
    DRUG INTERACTION POTENTIAL OF EMTRICITABINE (F; FTC)/TENOFOVIR (TFV) ALAFENAMIDE (TAF) (F/TAF) FIXED DOSE COMBINATION AND COBICISTAT (COBI)-BOOSTED DARUNAVIR (DRV).
  165. PII-045
    SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISITCS OF VVZ-149 INJECTION IN HEALTHY SUBJECTS.
  166. PII-046
    NO DOSE ADJUSTMENT IS NEEDED WHEN COADMINISTERING DULAGLUTIDE WITH A COMBINATION ORAL CONTRACEPTIVE.
  167. PII-047
    SITE OF INJECTION DOES NOT AFFECT DULAGLUTIDE PHARMACOKINETICS.
  168. PII-048
    POPULATION PHARMACODYNAMIC MODELING OF LANREOTIDE AUTOGEL IN JAPANESE ACROMEGALIC PATIENTS.
  169. PII-049
    A TARGET MEDIATED DRUG DISPOSITION (TMDD) DOSE OPTIMIZATION OF RG7116, A HER3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS EXPRESSING HER3.
  170. PII-050
    EFFECTS OF ETHANOL ON ASPIRIN HYDROLYSIS BY CARBOXYLESTERASE-2 IN HUMANS.
  171. PII-051
    APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DRUG INTERACTIONS AS CYP3A SUBSTRATE.
  172. PII-052
    APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DISEASE INTERACTION IN ORGAN DYSFUNCTION PATIENTS.
  173. PII-053
    PHARMACOKINETICS AND TOLERABILITY OF IDP-73152 MESYLATE AFTER A SINGLE ORAL ADMINISTRATION UNDER FASTING AND FED CONDITIONS IN HEALTHY VOLUNTEERS.
  174. PII-054
    A MULTIPLE-DOSE STUDY OF BLOCKADE OF OPIOID SUBJECTIVE EFFECTS BY SUBCUTANEOUS INJECTIONS OF DEPOT BUPRENORPHINE IN SUBJECTS WITH OPIOID USE DISORDER.
  175. PII-055
    INFORMATIVE DROPOUT MODELING AND EXPOSURE-RESPONSE ANALYSIS FOR MAVRILIMUMAB PHASE IIB STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
  176. PII-056
    MODELING AND SIMULATION-GUIDED RATIONAL DRUG DISCOVERY AND DEVELOPMENT: A CASE STUDY OF MAVRILIMUMAB.
  177. PII-057
    ASSESSING SYNERGY OF DRUG AGONISTS USING A SURFACE RESPONSE ANALYSIS IN R.
  178. PII-058
    EFFECT OF NEOMYCIN (N) ON THE PHARMACOKINETICS (PK) OF REGORAFENIB (REG).
  179. PII-059
    POPULATION PHARMACOKINETIC ANALYSIS OF SUMATRIPTAN IN HEALTHY KOREAN MALE SUBJECTS.
  180. PII-060
    EVALUATION OF THE TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORALLY ADMINISTERED DWP05195, A NEW TRPV1 ANTAGONIST IN HEALTHY ADULT MALE VOLUNTEERS.
  181. PII-061
    POPULATION PHARMACOKINETICS OF CIPROFLOXACIN AND DOSING RECOMMENDATION IN NEONATES AND INFANTS LESS THAN 3 MONTHS OF AGE.
  182. PII-062
    DRUG-DRUG INTERACTIONS OF OMEPRAZOLE WITH THE HCV DIRECT ACTING ANTIVIRAL (DAA) COMBINATION OF ABT-450/R, OMBITASVIR AND DASABUVIR.
  183. PII-063
    CONCENTRATION-QTc MODELING IN FIRST-IN-HUMAN STUDY TO ASSESS THE EFFECT OF THE INVESTIGATIONAL DRUG GS-4997 ON CARDIAC REPOLARIZATION.
  184. PII-064
    CLINICAL PHARMACOKINETICS STUDIES AIMED AT EFFECTIVELY AND EFFICIENTLY MONITORING THERAPEUTIC DRUG MONITORING METHOD OF MYCOPHENOLIC ACID IN RENAL TRANSPLANT RECIPIENTS.
  185. PII-065
    PHARMACOMETRICS ENABLED RATIONAL DETERMINATION OF OPTIMAL DOSING REGIMEN FOR BENRALIZUMAB PIVOTAL STUDIES IN ADULTS AND ADOLESCENTS WITH ASTHMA.
  186. PII-066
    THE PAN-PHOSPHOINOSITIDE-3 KINASE INHIBITOR PICTILISIB (GDC-0941), AN <i>IN VITRO</i> CYP2C8 INHIBITOR, DOES NOT IMPACT THE PHARMACOKINETICS OF PACLITAXEL, A CYP2C8 SUBSTRATE.
  187. PII-067
    BIOEQUIVALENCE OF ROSUVASTATIN/EZETIMIBE COMBINATION TABLETS AND CO-ADMINISTRATION OF ROSUVASTATIN AND EZETIMIBE IN HEALTHY KOREAN SUBJECTS.
  188. PII-068
    POPULATION PHARMACOKINETIC-PHARMACODYNAMIC (PKPD) MODELING OF AMG 747, A GLYCINE TRANSPORTER TYPE 1 (GLYT 1) INHIBITOR, IN HEALTHY SUBJECTS.
  189. PII-069
    CLINICAL PHARMACOLOGY STUDY OF TELAPREVIR IN HEALTHY KOREAN VOLUNTEERS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS.
  190. PII-070
    BIOEQUIVALENCE AND PHARMACOKINETIC EVALUATION OF TWO FORMULATIONS OF ULTRACET® ER TABLET.
  191. PII-071
    APPLICATION OF PBPK AND BAYESIAN MODELING FOR PREDICTION OF THE LIKELIHOOD OF INDIVIDUAL PATIENTS EXPERIENCING SERIOUS ADVERSE REACTIONS TO A STANDARD DOSE OF EFAVIRENZ.
  192. PII-072
    SERUM HEMOGLOBIN IS A PREDICTOR OF TACROLIMUS WHOLE BLOOD CONCENTRATION IN HEMATOPOEITIC STEM CELL TRANSPLANT PATIENTS.
  193. PII-073
    ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN THE PI3K INHIBITOR TASELISIB (GDC-0032) AND A STRONG CYP3A4 INDUCER OR INHIBITOR.
  194. PII-074
    PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROM A PHASE II, OPEN-LABEL STUDY.
  195. PII-075
    ASSESSMENT OF ABSOLUTE BIOAVAILABILITY AND MASS BALANCE OF THE PI3K INHIBITOR TASELISIB (GDC-0032) IN HEALTHY SUBJECTS.
  196. PII-076
    POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING FOR AN ANTISENSE OLIGONUCLEOTIDE (ISIS-FXIRx), TARGETING FACTOR XI, IN HEALTHY SUBJECTS.
  197. PII-077
    PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERBILITY PROFILES OF CKD-11101, A BIOSIMILAR TO NESP<sup>®</sup>, AFTER A SINGLE SUBCUTANEOUS ADMINISTRATION IN HEALTHY VOLUNTEERS.
  198. PII-078
    POPULATION PHARMACOKINETICS OF KRN23, A HUMAN ANTI-FGF23 ANTIBODY DEVELOPED FOR THE TREATMENT OF ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
  199. PII-079
    IMMUNOGENICITY AND TOLERABILITY OF NOVEL HUMAN PAPILLOMAVIRUS-16/18 VACCINE IN HEALTHY MALE VOLUNTEERS.
  200. PII-080
    PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERBILITY PROFILES OF CKD-11101, A BIOSIMILAR TO NESP®, AFTER A SINGLE INTRAVENOUS ADMINISTRATION IN HEALTHY VOLUNTEERS.
  201. PII-081
    EFFECT OF ACID REDUCING AGENTS ON THE PHARMACOKINETICS OF IDELALISIB, A NOVEL PI3Kδ INHIBITOR, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
  202. PII-082
    PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND SAFETY OF BMS-938790 IN HEALTHY SUBJECTS.
  203. PII-083
    PHARMACOKINETIC COMPARISON OF COMPOUND K AFTER ORAL ADMINISTRATION OF FERMENTED RED GINSENG EXTRACTS, RED GINSENG EXTRACTS AND GINSENG EXTRACTS IN HEALTHY SUBJECTS.
  204. PII-084
    EFFECT OF INTRINSIC AND EXTRINSIC FACTORS ON PHARMACOKINETICS OF IDELALISIB, A NOVEL PI3Kδ INHIBITOR, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
  205. PII-085
    PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA PATIENTS AGED 60 AND ABOVE.
  206. PII-086
    POPULATION PHARMACOKINETICS OF TD-9855, A NOREPINEPHRINE AND SEROTONIN REUPTAKE INHIBITOR (NSRI), IN HEALTHY SUBJECTS AND PATIENTS WITH ADULT ADHD OR FIBROMYALGIA.
  207. PII-087
    POPULATION PHARMACOKINETICS OF BELIMUMAB IN HEALTHY AMERICAN AND JAPANESE SUBJECTS FOLLOWING SUBCUTANEOUS ADMINISTRATION.
  208. PII-088
    EFFECT OF RENAL AND HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF CABOZANTINIB (CABO).
  209. PII-089
    PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) ANALYSES OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST EFFECT ON CORTISOL.
  210. PII-090
    POTENTIAL PRASUGREL DRUG INTERACTIONS BASED ON INHIBITION OF CARBOXYLESTERASE-2.
  211. PII-091
    POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF ECULIZUMAB TO SUPPORT PHASE III DOSING REGIMEN IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS.
  212. PII-092
    A PHASE I, OPEN-LABEL STUDY TO DETERMINE THE EFFECT OF SYM-1219 ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2) AND NORETHINDRONE (NET) IN HEALTHY FEMALE VOLUNTEERS.
  213. PII-093
    ATAZANAVIR ABSORPTION IN HEALTHY VOLUNTEERS WITH PHARMACOLOGICALLY-INDUCED HYPOCHLORHYDRIA USING BETAINE HCL.
  214. PII-094
    A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PREDICTION OF PLASMA AND LUNG CONCENTRATIONS AFTER ADMINISTRATION OF CEFTAZIDIME.
  215. PII-095
    POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ASSESSMENT OF ANTI-CD79B ANTIBODY DRUG CONJUGATE IN PATIENTS: INTERIM ANALYSIS RESULTS.
  216. PII-096
    PHARMACOKINETICS AND SAFETY OF SINGLE ASCENDING DOSES, FOOD EFFECT AND KETOCONAZOLE (KTZ) INTERACTION OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST ABT-436.
  217. PII-097
    PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF HUMAN ANTI-FGF23 ANTIBODY (KRN23) AND SERUM PHOSPHORUS IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
  218. PII-098
    PHARMACOKINETICS (PK) AND SAFETY OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST ABT-436 IN HEALTHY VOLUNTEERS FOLLOWING MULTIPLE DOSES.
  219. PII-099
    A CONCENTRATION-QTC ANALYSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING CRIZOTINIB: ACCOUNTING FOR BIAS IN CORRECTION METHODS.
  220. PII-100
    OPPOSITE EFFECTS OF ST. JOHN’S WORT AND RIFAMPIN ON GLUCOSE METABOLISM IN HEALTHY VOLUNTEERS.
  221. PII-101
    AZITHROMYCIN IS NOT ASSOCIATED WITH QT PROLONGATION IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA.
  222. PII-102
    THE CATASTROPHIC FIRST-IN-HUMAN TGN1412 TRIAL; A SYSTEMATIC REVIEW OF PUBLICATION PATTERNS AND LESSONS LEARNED SINCE THE 2006 INCIDENT.
  223. PII-103
    EVALUATION OF THE QTC PROLONGATION POTENTIAL OF TWO NEUROPSYCHIATRIC DRUGS QUETIAPINE AND ESCITALOPRAM IN HEALTHY VOLUNTEERS.
  224. PII-104
    ASSOCIATION OF MEGALIN GENETIC POLYMORPHISMS WITH ACUTE KIDNEY INJURY (AKI) IN AMINOGLYCOSIDE (AG)-TREATED NEWBORNS.
  225. PII-105
    THE PHARMACOGENETICS OF CODEINE PAIN RELIEF IN THE POSTPARTUM PERIOD.
  226. PII-106
    STEADY-STATE PHARMACOKINETICS OF GSK1278863 AND METABOLITES IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL FUNCTION.
  227. PII-107
    ANALYSIS OF THE EFFECT OF VARIOUS DEGREES OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF NONRENALLY ELIMINATED DRUGS.
  228. PII-108
    AGE-DEPENDENT CHANGES IN CYP3A METABOLIC CAPACITY DETERMINE SIROLIMUS CLEARANCE IN PEDIATRIC PATIENTS.
  229. PII-109
    THE EFFECT OF HEPATIC IMPAIRMENT (HI) OR HCV INFECTION ON THE PHARMACOKINETICS (PK) OF BUPRENORPHINE AND NALOXONE.
  230. PII-110
    PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST ADMINISTERED TO FEMALE SUBJECTS WITH HEPATIC IMPAIRMENT.
  231. PII-111
    PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST, ADMINISTERED TO FEMALE SUBJECTS WITH RENAL IMPAIRMENT.
  232. PII-112
    PHARMACOKINETICS OF SINGLE DOSE ESCITALOPRAM IN THE HEALTHY ELDERLY COMPARED WITH THE YOUNG.
  233. PII-113
    PHARMACOKINETICS (PK) OF TWO 6-MERCAPTOPURINE (6-MP) LIQUID FORMULATIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
  234. PII-114
    ELUCIDATION OF THE MECHANISM OF THERAPEUTIC PROTEIN-DRUG INTERACTION (TPDI) BETWEEN METHOTREXATE (MTX) AND AN ANTI-TNFα MONOCLONAL ANTIBODY (MAB), GOLIMUMAB.
  235. PII-115
    IMMUNOGENICITY OF NIVOLUMAB AND ITS IMPACT ON PHARMACOKINETICS (PK) AND SAFETY IN SUBJECTS WITH METASTATIC SOLID TUMORS.
  236. PII-116
    PHARMACOKINETICS AND PHARMACODYNAMICS OF BENRALIZUMAB IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
  237. PII-117
    ABSENCE OF QT PROLONGATION (QTP) EFFECT BY NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) IN SUBJECTS WITH SOLID TUMORS.
  238. PII-118
    ASSESSMENT OF DRUG INTERACTION POTENTIAL BY NIVOLUMAB USING CYTOKINE MODULATION DATA.
  239. PII-119
    ASSESSMENT OF CLINICAL RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BETWEEN PF-05280586, A PROPOSED BIOSIMILAR TO RITUXIMAB AND TWO RITUXIMAB PRODUCTS.
  240. PT-01
    INTEGRATING METABOLOMICS AND GENOMICS REVEALS NOVEL BIOMARKERS OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
  241. PT-02
    USING ELECTRONIC HEALTH RECORDS TO IDENTIFY DISEASE-SPECIFIC EFFECTS OF METFORMIN IN BREAST CANCER PATIENTS WITH TYPE II DIABETES MELLITUS.
  242. PT-03
    MARS (META-ANALYSIS USING R SHINY): A BROWSER BASED META-ANALYSIS MODELING VISUALIZATION APPLICATION.
  243. PT-04
    USE OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR-TRANSCRIPTION FACTORS (TALE-TFS) AS A NEW TECHNIQUE TO INDUCE CYP GENE EXPRESSION AND VALIDATE MIRNA PREDICTIONS.
  244. PT-05
    PREDICTIVE PERFORMANCE OF PHYSIOLOGICALLY BASED PHARMACOKINETC (PBPK) MODELS FOR THE EFFECT OF CYP 3A INDUCERS ON SUBSTRATE DRUGS: ANALYSIS OF SUBMISSIONS TO THE FDA.
  245. PT-06
    A MULTICENTER VALIDATION STUDY OF GENETIC POLYMORPHISMS ASSOCIATED WITH TOXICITY AND EFFICACY OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA .
  246. PT-07
    CHARACTERIZATION OF THE RELATIONSHIP BETWEEN BIOMARKERS OF CYTOCHROME P450-MEDIATED EICOSANOID METABOLISM AND CORONARY ARTERY DISEASE SEVERITY IN HUMANS.
  247. PT-08
    AROMATASE INHIBITOR-INDUCED ARTHRALGIA ASSOCIATED WITH TCL1A SNP AND ESTROGEN-DEPENDENT VARIATION IN CYTOKINE EXPRESSION: POSSIBLE LINKS BETWEEN ESTROGEN AND ARTHRITIS.
  248. PT-09
    A NOVEL HUMAN MODEL TO ASSESS REVERSAL OF OPIOID EFFECTS.
  249. PT-10
    PHARMACOGENETICS AND RACIAL COMPOSITION IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER AND CHRONIC HEPATITIS C INFECTION.
  250. PT-11
    THE PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP OF ETHOSUXIMIDE IN CHILDREN WITH CHILDHOOD ABSENCE EPILEPSY.
  251. PT-12
    TRYPTOPHAN METABOLITE RATIO PHARMACOGENOMICS AND PHARMACOMETABOLOMICS: SOD2 AS A MARKER FOR SSRI RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD).
  252. PT-13
    ENDOTOXIN MODULATES THE RENAL EXPRESSION OF DRUG TRANSPORTERS IN A HIV-1 TRANSGENIC RAT MODEL.
  253. PT-14
    PYRIMETHAMINE, A MATE TRANSPORTER INHIBITOR, INCREASES THE SYSTEMIC EXPOSURE TO METFORMIN BUT DOES NOT INCREASE ITS BLOOD GLUCOSE LOWERING ACTION.
  254. PT-15
    USING PBPK MODELING TO EXPLORE THE IMPACT OF ROUTE OF ADMINISTRATION ON THE METABOLIC DRUG-DRUG INTERACTION (DDI) BETWEEN MIDAZOLAM (MDZ) AND FLUCONAZOLE (FLZ).
  255. PT-16
    ANTIFUNGAL EXTRACTION BY THE EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) CIRCUIT <i>EX VIVO</i>.
  256. PT-17
    PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
  257. PT-18
    ASSESSMENT OF NEW GENOMIC BIOMARKERS OF DRUG-INDUCED LIVER INJURY AFTER ADMINISTRATION OF AMOXICILLIN/CLAVULANIC ACID IN HUMAN SUBJECTS.
  258. PT-19
    DEVELOPMENTAL TRAJECTORY OF INDIVIDUAL SIROLIMUS CLEARANCE IN NEONATES AND INFANTS WITH VASCULAR ANOMALIES.
  259. PT-20
    CORRELATING THE MELATONIN (MT) PATHWAY WITH ATENOLOL ASSOCIATED GLUCOSE DYSREGULATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
  260. PT-21
    ARYL HYDROCARBON RECEPTOR (AHR) GENETIC VARIATION ASSOCIATED WITH KYNURENINE LEVELS IN MAJOR DEPRESSIVE DISORDER: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS.
  261. PT-22
    TRENDS IN US CHILDHOOD VACCINATION PRACTICES AND OUTBREAKS OF VACCINE-PREVENTABLE DISEASES, 2006-2010.
  262. PW-01
    SYSTEMS PHARMACOLOGY MODELING OF HYPOMETHYLATING AGENTS DECITABINE & SGI-110 FOR EVALUATION OF AML TREATMENT BY TARGETING S-PHASE WITH PROLONGED PHARMACOKINETIC EXPOSURES.
  263. PW-02
    PK/PD MEDIATED DOSE OPTIMIZATION OF RG7155, A CSF1R INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS AND PVNS (PIGMENTED VILLONODULAR SYNOVITIS).
  264. PW-03
    NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
  265. PW-04
    A MULTICENTER VALIDATION STUDY OF GENETIC POLYMORPHISMS ASSOCIATED WITH TOXICITY AND EFFICACY OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA .
  266. PW-05
    PHARMACOGENETICS AND RACIAL COMPOSITION IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER AND CHRONIC HEPATITIS C INFECTION.
  267. PW-06
    APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING FOR PREDICTION OF BUPRENORPHINE EXPOSURE IN NEONATES: INCORPORATION OF CYP3A4 AND UGT1A1 ONTOGENIES.
  268. PW-07
    SINGLE DOSE PHARMACOKINETICS OF ATOMOXETINE IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) STRATIFIED BY THEIR CYP2D6 ACTIVITY SCORE (AS).
  269. PW-08
    PEDIATRIC MICRODOSE STUDY OF [14C]PARACETAMOL TO STUDY DRUG METABOLISM USING ACCELERATED MASS SPECTROMETRY: PROOF OF CONCEPT.
  270. PW-09
    THE PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP OF ETHOSUXIMIDE IN CHILDREN WITH CHILDHOOD ABSENCE EPILEPSY.
  271. PW-10
    PHARMACOKINETICS OF MICAFUNGIN IN INFANTS SUPPORTED WITH EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO).
  272. PW-11
    MEASURING THE QUALITY OF ORAL ANTICOAGULATION AMONG HOSPITALIZED PATIENTS: A ONE-YEAR RETROSPECTIVE ANALYSIS.
  273. PW-12
    USING ELECTRONIC HEALTH RECORDS TO IDENTIFY DISEASE-SPECIFIC EFFECTS OF METFORMIN IN BREAST CANCER PATIENTS WITH TYPE II DIABETES MELLITUS.
  274. PW-13
    TYROSINE KINASE TARGETING DRUGS-ASSOCIATED CONGESTIVE HEART FAILURE: TRASTUZUMAB, CETUXIMAB, PANITUMUMAB AND SUNITINIB ARE ASSOCIATED WITH INCREASED RISK.
  275. PW-14
    RISKS OF CONGENITAL MALFORMATIONS IN OFFSPRING EXPOSED TO VALPROIC ACID IN UTERO: A SYSTEMATIC REVIEW AND CUMULATIVE META-ANALYSIS.
  276. PW-15
    APIXABAN FOR TREATMENT OF VENOUS THROMBOEMBOLISM (VTEtx): USE OF MODEL-BASED META-ANALYSES (MBMA) TO SUPPORT PHASE III DOSE SELECTION.
  277. QP-01
    MODELING AND SIMULATION-GUIDED RATIONAL DRUG DISCOVERY AND DEVELOPMENT: A CASE STUDY OF MAVRILIMUMAB.
  278. QP-02
    ASSESSING SYNERGY OF DRUG AGONISTS USING A SURFACE RESPONSE ANALYSIS IN R.
  279. QP-03
    APPLICATION OF PBPK AND BAYESIAN MODELING FOR PREDICTION OF THE LIKELIHOOD OF INDIVIDUAL PATIENTS EXPERIENCING SERIOUS ADVERSE REACTIONS TO A STANDARD DOSE OF EFAVIRENZ.
  280. QP-04
    INTEGRATING METABOLOMICS AND GENOMICS REVEALS NOVEL BIOMARKERS OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
  281. QP-05
    SYSTEMS PHARMACOLOGY MODELING OF HYPOMETHYLATING AGENTS DECITABINE & SGI-110 FOR EVALUATION OF AML TREATMENT BY TARGETING S-PHASE WITH PROLONGED PHARMACOKINETIC EXPOSURES.
  282. QP-06
    PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF HUMAN ANTI-FGF23 ANTIBODY (KRN23) AND SERUM PHOSPHORUS IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
  283. QP-07
    PHARMACOMETABOLOMICS STUDY: REVEALS THAT METFORMIN TREATMENT IMPACTS THE UREA CYCLE.
  284. QP-08
    A PHARMACOMETRICS APPROACH COMBINED WITH VARIOUS GENETIC ANALYSES UNCOVERS GENES LINKED TO THE DYNAMICS OF HBA1C.
  285. QP-09
    OXYLIPID PROFILE OF LOW-DOSE ASPIRIN EXPOSURE- A PHARMACOMETABOLOMICS STUDY.
  286. QP-10
    USING PBPK MODELING TO EXPLORE THE IMPACT OF ROUTE OF ADMINISTRATION ON THE METABOLIC DRUG-DRUG INTERACTION (DDI) BETWEEN MIDAZOLAM (MDZ) AND FLUCONAZOLE (FLZ).
  287. QP-11
    METABOLOMICS, GENOMICS AND LIPIDOMICS REVEAL NOVEL SIGNATURES OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
  288. QP-12
    UNDERSTANDING OF GFR (GLOMERULAR FILTRATION RATE) CHANGES IN RESPONSE TO ARB ADMINISTRATION USING QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH.
  289. QP-13
    PBPK MODELLING AND SIMULATION IN CHILDREN FOR TAPENTADOL METABOLIZED THROUGH GLUCURONIDATION.
  290. QP-14
    QUANTITATIVE MECHANISTIC STATIC MODEL FOR THE PREDICTION OF HUMAN RENAL ORGANIC ANION TRANSPORTER (OAT)-MEDIATED DRUG INTERACTIONS.
  291. QP-15
    SIMULATING CARDIAC CONSEQUENCES OF THE GENETIC VARIABILITY AT THE METABOLISM LEVEL WITH USE OF MIDDLE-OUT APPROACH AND FLECAINIDE AS AN EXAMPLE COMPOUND.
  292. QP-16
    CHARACTERIZING THE CHANGES IN DRUG CLEARANCE FROM NEONATES TO ADULTS BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING USING GASTROPLUS.
  293. QP-17
    SYSTEMS PHARMACOLOGY MODELING OF ACUTE LYMPHOBLASTIC LEUKEMIA PROGRESSION AND TREATMENT.
  294. QP-18
    THE SYSTEMS PHARMACOLOGY MODEL OF HEPATITIS C PROGRESSION AND TREATMENT.
  295. QP-19
    NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
  296. QP-20
    GENOME WIDE ASSOCIATION ANALYSIS WITH AMINE METABOLITES REVEALS NOVEL LOCI IMPACTING HUMAN METABOLOMIC PROFILES.
  297. QP-21
    MARS (META-ANALYSIS USING R SHINY): A BROWSER BASED META-ANALYSIS MODELING VISUALIZATION APPLICATION.
  298. QP-22
    IMPACT OF ALTERED IN VITRO DISSOLUTION PROFILE ON WARFARIN IN VIVO PHARMACOKINETICS PERFORMANCE- POPULATION PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) SIMULATION.
  299. QP-23
    PHYSIOLOGICALLY-BASED ABSORPTION MODELING AND SIMULATION FOR ASSESSING BIOAVAILABILITY IN ELDERLY, CHILDREN AND GASTROINTESTINAL DISEASES.
  300. QP-24
    SEARCHING FOR OPTIMAL THERAPY OF THE AMYLOID PATHOLOGY USING MECHANISM-BASED MODEL.
  301. QP-25
    P-MAP: NETWORK BIOLOGY APPLIED TO DETERMINE CELLULAR SENSITIVITY OF DRUG RESPONSE IN TRIPLE NEGATIVE BREAST CANCER CELL LINES.
  302. QP-26
    DEVELOPMENT OF A HUMAN WHOLE-BODY PHYSIOLOGICALLY-BASED PHARMACOKINETIC (WB-PBPK) MODEL OF LOVASTATIN LACTONE AND CARBOXYLATE (ACID) TO PREDICT HEPATIC CONCENTRATIONS.
  303. QP-27
    REVIEW: WORKFLOW AND TECHNICAL METHODOLOGIES FOR ROBUST APPLICATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACHES IN MODEL-BASED DRUG DEVELOPMENT.
  304. QP-28
    A CLINICAL-DATA DRIVEN MECHANISTIC SYSTEMS MODEL OF ASTHMA DISEASE AND TREATMENT.
  305. QP-29
    NETWORK-BASED SYSTEMS PHARMACOLOGY APPROACH FOR TARGET IDENTIFICATION IN HETEROGENEOUS NON-HODGKIN’S LYMPHOMA.
  306. QP-30
    VIRTUAL SYSTEMS PHARMACOLOGY (VISP) FLEXIBLE WEB-BASED ENVIRONMENT FOR RUNNING LARGE MULTI-SCALE MODELS.
  307. QP-31
    REVIEW AND APPLICATION OF A THEORETICAL FRAMEWORK TO ASSESS PARAMETER IDENTIFIABILITY AND SUBSET SELECTION IN SYSTEMS PHARMACOLOGY MODELS.
  308. QP-32
    DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY PLATFORM TO SUPPORT TRANSLATIONAL RESEARCH AND CLINICAL DEVELOPMENT IN IMMUNO-ONCOLOGY.
  309. LBPW-1
    RESULTS FROM THE IQ-CSRC PROSPECTIVE STUDY SUPPORT REPLACEMENT OF THE THOROUGH QT STUDY BY QT ASSESSMENT IN THE EARLY CLINICAL PHASE.
  310. LBPW-2
    GENETIC VARIANT IN FOLATE HOMEOSTASIS IS ASSOCIATED WITH LOWER WARFARIN DOSE IN AFRICAN AMERICANS.
  311. LBPW-3
    CARBOXYLESTERASE 1 C.428G>A SINGLE NUCLEOTIDE VARIATION INCREASES THE ANTIPLATELET EFFECTS OF CLOPIDOGREL BY REDUCING ITS HYDROLYSIS IN HUMANS.
  312. LBPW-4
    FEWER CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION WITH GENOTYPE-GUIDED ANTIPLATELET THERAPY: RESULTS FROM THE UF HEALTH PERSONALIZED MEDICINE PROGRAM.
  313. LBPW-5
    GLUCURONIDATION CONVERTS CLOPIDOGREL TO A STRONG METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: A PHASE II METABOLITE AS A CAUSE OF DRUG-DRUG INTERACTIONS.